|
|
|
|
|
27.10.26 - 12:31
|
InflaRx Announces November Investor Events (GlobeNewswire EN)
|
|
|
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November....
|
|
|
22.10.26 - 18:02
|
InflaRx Highlights Izicopan′s Therapeutic Potential at Kidney Week 2026 (GlobeNewswire EN)
|
|
|
Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases....
|
|
|
02.10.26 - 13:33
|
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 (GlobeNewswire EN)
|
|
|
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25....
|
|
|
01.10.26 - 13:31
|
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development (GlobeNewswire EN)
|
|
|
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026....
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.26 - 13:33
|
InflaRx to Report Second Quarter 2026 Results on August 6, 2026 (GlobeNewswire EN)
|
|
|
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. No conference call is planned....
|
|
|
|
|
|
|
08.05.26 - 14:18
|
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares (GlobeNewswire EN)
|
|
|
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses....
|
|
|
07.05.26 - 12:12
|
InflaRx sichert sich 150 Mio. USD frisches Kapital (GoingPublic)
|
|
|
Bildnachweis: InflaRx, stock3.com. Das deutsch-amerikanische Biotech-Unternehmen InflaRx (ISIN: NL0012661870, MarketCap am 7.5.26: 180,73 Mio. USD) hat gestern (6.5.26) eine Kapitalerhöhung über 150 Mio. USD angekündigt. Die Finanzierung zählt zu den […]
Der Beitrag InflaRx sichert sich 150 Mio. USD frisches Kapital erschien zuerst auf GoingPublic.de....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
